<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460302</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>The Influence of Initial Immunosuppression on the Kinetics of Humoral Response after SARS-CoV-2 Vaccination in Patients Undergoing Kidney Transplantation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1135</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101135</ELocationID><Abstract><AbstractText><b>Background:</b> The effect of initial immunosuppressive therapy on the kinetics of the SARS-CoV-2 vaccine-induced humoral response is unknown. Here, we compared the kinetics of SARS-CoV-2 vaccine-induced humoral response in chronic kidney disease patients undergoing kidney transplantation (KTRs) and compared to patients remaining on dialysis during the Omicron circulation. <b>Methods:</b> This prospective, non-randomized, real-world study included 113 KTRs and 108 patients on dialysis. Those with previous COVID-19 or negative IgG at screening were excluded. Blood samples were collected to assess SARS-CoV-2 IgG titers and neutralizing antibodies at months (M) 1, 3, 6, and 12. <b>Results:</b> Seroreversion occurred in one KTR and in three patients on dialysis. KTRs had lower IgG titers over time (M1: 10,809.3 ± 12,621.7 vs. 15,267.8 ± 16,096.2 AU/mL; M3: 12,215.5 ± 12,885.8 vs. 15,016.2 ± 15,346.1 AU/mL; M6: 12,540.4 ± 13,010.7 vs. 18,503.5 ± 14,581.0 AU/mL; <i>p</i> = 0.005), but neutralizing antibodies were similar (M1: 94.0 vs. 90.3%; M3: 92.9 vs. 90.5%; M6: 99.0 vs. 95.5%; M12: 98.9 vs. 97.5%; <i>p</i> = 0.812). During follow-up, KTRs received more vaccines (141 vs. 73; <i>p</i> &lt; 0.001) and contracted more COVID-19 (32.7% vs. 14.8%; <i>p</i> = 0.002). <b>Conclusions:</b> Compared to patients on dialysis, KTRs had lower SARS-CoV-2 IgG titers and similar rates of seroreversion and neutralizing antibodies over time. Although KTRs received more boosters, they had a higher incidence of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Foresto</LastName><ForeName>Renato Demarchi</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0001-9370-0265</Identifier><AffiliationInfo><Affiliation>Nephrology Division, Universidade Federal de São Paulo, 960 Borges Lagoa Street, São Paulo 04038-002, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Roberto Matias</ForeName><Initials>RM</Initials><Identifier Source="ORCID">0000-0001-7019-6174</Identifier><AffiliationInfo><Affiliation>Nephrology Division, Universidade Federal de São Paulo, 960 Borges Lagoa Street, São Paulo 04038-002, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dos Anjos</LastName><ForeName>Gustavo Rodrigues</ForeName><Initials>GR</Initials><Identifier Source="ORCID">0009-0005-6410-8111</Identifier><AffiliationInfo><Affiliation>Nephrology Division, Universidade Federal de São Paulo, 960 Borges Lagoa Street, São Paulo 04038-002, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Mônica Rika</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goulart</LastName><ForeName>Haryanne de Souza</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampaio</LastName><ForeName>Rayra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>França</LastName><ForeName>Daniela Pereira</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Emanuelle Ferreira</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucena</LastName><ForeName>Elisabeth França</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristelli</LastName><ForeName>Marina Pontello</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-2813-0400</Identifier><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedesco Silva</LastName><ForeName>Helio</ForeName><Initials>H</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0002-9896-323X</Identifier><AffiliationInfo><Affiliation>Nephrology Division, Universidade Federal de São Paulo, 960 Borges Lagoa Street, São Paulo 04038-002, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Requião-Moura</LastName><ForeName>Lúcio</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-8751-9048</Identifier><AffiliationInfo><Affiliation>Nephrology Division, Universidade Federal de São Paulo, 960 Borges Lagoa Street, São Paulo 04038-002, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pestana</LastName><ForeName>José Medina</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-0750-7360</Identifier><AffiliationInfo><Affiliation>Nephrology Division, Universidade Federal de São Paulo, 960 Borges Lagoa Street, São Paulo 04038-002, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04039-000, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021/13680-6</GrantID><Agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</Agency><Country /></Grant><Grant><GrantID>001</GrantID><Agency>National Council for Scientific and Technological Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">dialysis</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword><Keyword MajorTopicYN="N">kidney transplant</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460302</ArticleId><ArticleId IdType="pmc">PMC11510881</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101135</ArticleId><ArticleId IdType="pii">vaccines12101135</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miyah Y., Benjelloun M., Lairini S., Lahrichi A. COVID-19 Impact on Public Health, Environment, Human Psychology, Global Socioeconomy, and Education. Sci. World J. 2022;2022:5578284. doi: 10.1155/2022/5578284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/5578284</ArticleId><ArticleId IdType="pmc">PMC8767375</ArticleId><ArticleId IdType="pubmed">35069037</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzi Y., Bartash R., Scalea J., Loarte-Campos P., Akalin E. COVID-19 and Solid Organ Transplantation: A Review Article. Transplantation. 2021;105:37–55. doi: 10.1097/TP.0000000000003523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003523</ArticleId><ArticleId IdType="pubmed">33148977</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sandes-Freitas T.V., de Andrade L.G.M., Moura L.R.R., Cristelli M.P., Medina-Pestana J.O., Lugon J.R., Ricardo Sesso For the Brazilian Covid-19 Dialysis Investigators and the Covid-19-KT Brazilian Study Group Comparison of 30-day case-fatality rate between dialysis and transplant Covid-19 patients: A propensity score matched cohort study. J. Nephrol. 2022;35:131–141. doi: 10.1007/s40620-021-01172-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-021-01172-1</ArticleId><ArticleId IdType="pmc">PMC8532104</ArticleId><ArticleId IdType="pubmed">34677805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestana J.M., Cristelli M.P., Tedesco Silva H., Jr. The Challenges of Risk Aversion in Kidney Transplantation: Lessons From the SARS-CoV-2 Pandemic in Brazil. Transplantation. 2024;108:813–818. doi: 10.1097/TP.0000000000004890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004890</ArticleId><ArticleId IdType="pubmed">38526427</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed-Ahmed M., Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Adv. Chronic Kidney Dis. 2019;26:8–15. doi: 10.1053/j.ackd.2019.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2019.01.004</ArticleId><ArticleId IdType="pubmed">30876622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders J.F., Messchendorp A.L., de Vries R.D., Baan C.C., van Baarle D., van Binnendijk R., Diavatopoulos D.A., Geers D., Schmitz K.S., GeurtsvanKessel C.H., et al. Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Clin. Infect. Dis. 2023;76:e188–e199. doi: 10.1093/cid/ciac557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac557</ArticleId><ArticleId IdType="pmc">PMC9278186</ArticleId><ArticleId IdType="pubmed">35796536</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong K., Peng D., Yang H., Huang Z., Luo Y., Wang Y., Xiang S., Li T., Mou T., Wu Z. Risk Factors for Weak Antibody Response of SARS-CoV-2 Vaccine in Adult Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis. Front Immunol. 2022;13:888385. doi: 10.3389/fimmu.2022.888385.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.888385</ArticleId><ArticleId IdType="pmc">PMC9237843</ArticleId><ArticleId IdType="pubmed">35774786</ArticleId></ArticleIdList></Reference><Reference><Citation>L’Huillier A.G., Ferreira V.H., Hirzel C., Nellimarla S., Ku T., Natori Y., Humar A., Kumar D. T-cell responses following Natural Influenza Infection or Vaccination in Solid Organ Transplant Recipients. Sci. Rep. 2020;10:10104. doi: 10.1038/s41598-020-67172-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67172-6</ArticleId><ArticleId IdType="pmc">PMC7308384</ArticleId><ArticleId IdType="pubmed">32572168</ArticleId></ArticleIdList></Reference><Reference><Citation>Loinaz C., de Juanes J.R., Gonzalez E.M., Lopez A., Lumbreras C., Gomez R., Gonzalez-Pinto I., Jiménez C., Garcia I., Fuertes A. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology. 1997;44:235–238.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dendle C., Stuart R.L., Mulley W.R., Holdsworth S.R. Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence. Vaccine. 2018;36:6253–6261. doi: 10.1016/j.vaccine.2018.08.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.08.069</ArticleId><ArticleId IdType="pubmed">30217523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszer K., Charland K., Pierce L., Saucier A., McKinnon B., Hamelin M.E., Cheriet I., Da Torre M.B., Carbonneau J., Nguyen C.T., et al. Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montreal, Canada. Int. J. Infect. Dis. 2023;131:119–126. doi: 10.1016/j.ijid.2023.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.03.036</ArticleId><ArticleId IdType="pmc">PMC10033142</ArticleId><ArticleId IdType="pubmed">36963656</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott  AdviseDx SARS-CoV-2 IgG II Instructions for Use.  [(accessed on 10 December 2021)];2021  Available online:  https://www.fda.gov/media/146371/download.</Citation></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I., Tiu C., Hu Z., Chen V.C.-W., Young B.E., Sia W.R., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 2020;38:1073–1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira-Silva T., Andrews J.R., Boaventura V.S., Ranzani O.T., de Araujo Oliveira V., Paixao E.S., Bertoldo Júnior J., Machado T.M., Hitchings M.D.T., Dorion M., et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: A test-negative, case-control study. Lancet Infect. Dis. 2022;22:791–801. doi: 10.1016/S1473-3099(22)00140-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00140-2</ArticleId><ArticleId IdType="pmc">PMC8971277</ArticleId><ArticleId IdType="pubmed">35366959</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Pestana J., Covas D.T., Viana L.A., Dreige Y.C., Nakamura M.R., Lucena E.F., Júnior J.B., Machado T.M., Hitchings M.D.T., Dorion M., et al. Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results. Transplantation. 2022;106:853–861. doi: 10.1097/TP.0000000000004036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004036</ArticleId><ArticleId IdType="pmc">PMC8942595</ArticleId><ArticleId IdType="pubmed">34882589</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrondal A., Rabe-Hesketh S. Generalized Latent Variable Modeling: Multilevel, Longitudinal and Structural Equation Models. Boca Chapman and Hall/CRC; Raton, FL, USA: 2004.</Citation></Reference><Reference><Citation>Gelman A., Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge University Press; Cambridge, UK: 2007.</Citation></Reference><Reference><Citation>Van Praet J., Reynders M., De Bacquer D., Viaene L., Schoutteten M.K., Caluwe R., Doubel P., Heylen L., De Bel A.V., Van Vlem B., et al. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. J. Am. Soc. Nephrol. 2021;32:3208–3220. doi: 10.1681/ASN.2021070908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021070908</ArticleId><ArticleId IdType="pmc">PMC8638385</ArticleId><ArticleId IdType="pubmed">34588184</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O’Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Guerrero-Arguero I., Velasco J.V., Ver A.T., Santos de Oliveira M.H., Catahay J.A., Khan M.M.S.R., Pastrana A., Juszczyk G., Torrelles J.B., et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J. Med. Virol. 2022;94:2939–2961. doi: 10.1002/jmv.27688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27688</ArticleId><ArticleId IdType="pmc">PMC9088566</ArticleId><ArticleId IdType="pubmed">35229324</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O’Connell A.-M., et al. COVID-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 2022;386:1532–1546. doi: 10.1056/NEJMoa2119451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2119451</ArticleId><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazit S., Shlezinger R., Perez G., Lotan R., Peretz A., Ben-Tov A., Herzel E., Alapi H., Cohen D., Muhsen K., et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. Clin. Infect. Dis. 2022;75:e545–e551. doi: 10.1093/cid/ciac262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac262</ArticleId><ArticleId IdType="pmc">PMC9047157</ArticleId><ArticleId IdType="pubmed">35380632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozkaya E., Yazici M., Baran I., Cetin N.S., Tosun I., Buruk C.K., Kaklıkkaya N., Aydın F. Neutralization of Wild-Type and Alpha SARS-CoV-2 Variant by CoronaVac(R) Vaccine and Natural Infection- Induced Antibodies. Curr. Microbiol. 2023;80:162. doi: 10.1007/s00284-023-03248-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-023-03248-6</ArticleId><ArticleId IdType="pmc">PMC10066983</ArticleId><ArticleId IdType="pubmed">37004596</ArticleId></ArticleIdList></Reference><Reference><Citation>Barin B., Kasap U., Selcuk F., Volkan E., Uluckan O. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: A prospective, longitudinal population-based study. Lancet Microbe. 2022;3:e274–e283. doi: 10.1016/S2666-5247(21)00305-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00305-0</ArticleId><ArticleId IdType="pmc">PMC8828370</ArticleId><ArticleId IdType="pubmed">35165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Seija M., Rammauro F., Santiago J., Orihuela N., Zulberti C., Machado D., Recalde C., Noboa J., Frantchez V., Astesiano R., et al. Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant. Clin. Kidney J. 2022;15:527–533. doi: 10.1093/ckj/sfab291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfab291</ArticleId><ArticleId IdType="pmc">PMC8755301</ArticleId><ArticleId IdType="pubmed">35198159</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Pestana J., Almeida Viana L., Nakamura M.R., Lucena E.F., Granato C.F.H., Dreige Y.C., Amorim L.V.P., Chow C.Y.Z., Demarchi Foresto R., Roberto Requião-Moura L., et al. Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac Vaccine: A Prospective Cohort Study. Transplantation. 2022;106:2076–2084. doi: 10.1097/TP.0000000000004260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000004260</ArticleId><ArticleId IdType="pmc">PMC9521386</ArticleId><ArticleId IdType="pubmed">35939382</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>